Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. The company is pursuing several first-in-class drug candidates. Inspirna's lead drug candidate, RGX-202-01, is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients where it enables the generation of the energy molecule ATP in response to tumor hypoxia. RGX-202-01 is currently being tested in a Phase 1b clinical trial in combination with standard-of-care FOLFIRI and bevacizumab for the second line treatment of patients with advanced or metastatic CRC.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/11/22 | $50,000,000 | Series D |
Dreavent 6 Lepu Holdings New York City Investment Fund Novo Holdings Sands Capital  Sixty Degree Capital Sofinnova Partners Vivo Capital | undisclosed |
